Literature DB >> 2476532

The cytotoxicity of a 2-chloroethylnitrosourea analog of sarcosinamide in the SK-MG-1 human glioma cell line as a possible indicator for transport.

V Skalski1, W Feindel, L C Panasci.   

Abstract

The cytotoxicities of a new sarcosinamide analog of chloroethylnitrosourea (SarCNU) and of BCNU were examined in the glioma cell line SK-MG-1 in the presence or absence of excess concentrations of amino acids and sarcosinamide. The cytotoxicity of SarCNU, but not of BCNU, was significantly reduced in the presence of excess sarcosinamide. The stability of SarCNU was not significantly altered by increasing concentrations of sarcosinamide. In order to investigate the possibility that sarcosinamide inhibits the uptake of SarCNU the transport of tritiated sarcosinamide was examined in SK-MG-1 cells. The uptake of 3H-sarcosinamide was inhibited by excess, unlabelled sarcosinamide and SarCNU but not by BCNU, glycine or sarcosine. These results suggest the existence of a carrier-mediated transport for sarcosinamide which can accomodate SarCNU in SK-MG-1 cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476532     DOI: 10.1007/bf00165103

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  13 in total

1.  A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice.

Authors:  L C Panasci; D Green; R Nagourney; P Fox; P S Schein
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

2.  Characterization of L-threonine and L-glutamine transport in murine P388 leukemia cells in vitro. Presence of an N-like amino acid transport system.

Authors:  P Lazarus; L C Panasci
Journal:  Biochim Biophys Acta       Date:  1986-04-25

3.  Primary bioassay of human myeloma stem cells.

Authors:  A Hamburger; S E Salmon
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

4.  Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU.

Authors:  L C Panasci; M Dufour; L Chevalier; G Isabel; P Lazarus; A McQuillan; E Arbit; S Brem; W Feindel
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  (2-Chloroethyl)nitrosourea congeners of amino acid amides.

Authors:  T Suami; T Kato; H Takino; T Hisamatsu
Journal:  J Med Chem       Date:  1982-07       Impact factor: 7.446

6.  Prospective clinical trial of a human tumor cloning system.

Authors:  D D Von Hoff; G M Clark; B J Stogdill; M F Sarosdy; M T O'Brien; J T Casper; D E Mattox; C P Page; A B Cruz; J F Sandbach
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

Review 7.  1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.

Authors:  S K Carter; F M Schabel; L E Broder; T P Johnston
Journal:  Adv Cancer Res       Date:  1972       Impact factor: 6.242

8.  The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man.

Authors:  V Skalski; J Rivas; L Panasci; A McQuillan; W Feindel
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

Authors:  S E Salmon; A W Hamburger; B Soehnlen; B G Durie; D S Alberts; T E Moon
Journal:  N Engl J Med       Date:  1978-06-15       Impact factor: 91.245

10.  Mechanism of uptake of nitrosoureas by L5178Y lymphoblasts in vitro.

Authors:  A Begleiter; H P Lam; G J Goldenberg
Journal:  Cancer Res       Date:  1977-04       Impact factor: 12.701

View more
  1 in total

1.  Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET.

Authors:  S Mitsuki; M Diksic; T Conway; Y L Yamamoto; J G Villemure; W Feindel
Journal:  J Neurooncol       Date:  1991-02       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.